id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-334175-x10bbv7y	Okur, Hacer Kuzu	Preliminary report of In vitro and In vivo Effectiveness of Dornase alfa on SARS-CoV-2 infection	2020-09-07		.txt	text/plain	4026	251	55	Dornase alfa, the recombinant form of the human DNase I enzyme, breaks down neutrophil extracellular traps (NET) that include a vast amount of DNA fragments, histones, microbicidal proteins and oxidant enzymes released from necrotic neutrophils in the highly viscous mucus of cystic fibrosis patients. We followed clinical improvement in the radiological analysis (2-of-3 cases), oxygen saturation (SpO2), respiratory rate, disappearing of dyspnea, coughing and a decrease in NET formation and SARS-CoV-2 viral load after the treatment. Also here, we share our preliminary results suggesting that Dornase alfa has an anti-viral effect against SARS-CoV-2 infection in a green monkey kidney cell line, Vero, and a bovine kidney cell line, MDBK without determined cytotoxicity on healthy peripheral blood mononuclear cells. In this study, preliminary data is presented about in-vitro and in-vivo anti-viral and nuclease activity of Dornase alfa for the clearance of SARS-CoV-2 viral load and NETs in the lungs of COVID-19 patients.	./cache/cord-334175-x10bbv7y.txt	./txt/cord-334175-x10bbv7y.txt